Policy & Regulation
Can-Fite reports preclinical data supporting Phase IIb pancreatic cancer study
17 August 2026 - Israel-based clinical-stage biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), which develops small-molecule drugs for oncological and inflammatory disea...
Acurx receives FDA conditional acceptance for ibezapolstat brand name
17 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) disclosed on Monday that it has received conditional FDA acceptance for CIFBEZY, the proposed proprietary name for i...
AstraZeneca reports positive Phase III results for Tagrisso and Orpathys
17 August 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday announced positive high-level results from the SAFFRON Phase III trial, showing Tagrisso (osimertinib...
OmniAb signs global ion channel collaboration with Eli Lilly
17 August 2026 - Research technology company OmniAb Inc (NASDAQ: OABI) disclosed on Monday that it has entered into a global collaboration and licence agreement with medicine firm Eli Lilly and Compan...
HUTCHMED reports positive Phase III results for ORPATHYS and TAGRISSO combination
17 August 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) on Monday announced positive high-level results from the SAFFRON Phase III trial, showing that O...
Phanes Therapeutics' Spevatamig receives US FDA Fast Track designation in advanced and metastatic biliary tract carcinoma
17 August 2026 - Phanes Therapeutics Inc, a California-based, clinical-stage biotech company involved in innovative drug discovery and development in immuno-oncology, announced on Friday that the US F...